BioSpace News Archive

Neuromagen Pharma Ltd., a company developing a new class of drugs for the treatment of degenerative and senescence-associated diseases, announced the establishment of a Scientific Advisory Board and the appointment of Prof. Gal Ifergane, Head of the Neurology Department at Soroka Medical Center as its first member.

Singapore-based SCG Cell Therapy Pte Ltd announced interim data from an investigator-initiated clinical trial of SCG101, which included data evaluating single dose SCG101 in patients with advanced hepatitis B related hepatocellular carcinoma.

CAPS Medical, developer of a highly selective and minimally invasive non-thermal plasma device for cancer treatment, announced the enrollment of the first patients in a multi-center study to assess the safety and technical performance of their NTAP™ system in the treatment of Non Muscle Invasive Bladder Cancer.

Cingulate Inc. today announced completion of the formulation study for its third asset, CTx-2103, for the management of anxiety-related disorders.

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced safety and biomarker data from 10 patients enrolled in the low-dose cohort of the ongoing Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease.

Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced the appointment of Douglas M. Fambrough, III, Ph.D. to its board of directors.

Cognition Therapeutics , Inc. (Nasdaq: CGTX) today announced that the first patient has been dosed in its double-blind, placebo-controlled, randomized Phase 2 SHIMMER clinical trial of CT1812 in patients with dementia with Lewy bodies (DLB).

ABOzymes Biomedical Inc., today announced it has completed a substantially upsized seed financing.

ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and the prevention of end-stage renal disease (ESRD) requiring dialysis or transplant, today published data from a patient study confirming the mechanistic action of its lead candidate REACT™ with cell marker analysis.

I-Mab (“I-Mab” or the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it was ranked among the top companies in five different categories by leading global financial publication.